SML2950
E7820
≥98% (HPLC)
别名:
3-Cyano-N-(3-cyano-4-methyl-1H-indol-7-yl)benzenesulfonamide, 3-Cyano-N-(3-cyano-4-methyl-1H-indole-7-yl)benzensulfonamide, E 7820, NSC 719239
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C17H12N4O2S
化学文摘社编号:
分子量:
336.37
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
ligand
E7820
Quality Level
assay
≥98% (HPLC)
form
powder
reaction suitability
reagent type: ligand
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[S](=O)(=O)(Nc2c3[nH]cc(c3c(cc2)C)C#N)c1cc(ccc1)C#N
InChI
1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3
InChI key
LWGUASZLXHYWIV-UHFFFAOYSA-N
Biochem/physiol Actions
E7820 (NSC 719239) is an orally available anticancer and antiangiogenic agent that inhibits VEGF-2 or FGF-2-induced tube formation of HUVEC cells through the suppression of integrin α2. E7820 promotes selective proteasomal degradation of the U2AF-related splicing factor CAPERα (coactivator of activating protein-1 and estrogen receptors) by ubiquitination and degradation via CRL4DCAF15.
inducer of selective proteasomal degradation of CAPERα
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Ken Ito et al.
Cancer science, 105(8), 1023-1031 (2014-05-21)
Most non-small-cell lung cancers (NSCLCs) harboring activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (EGFR-TKIs); however, they invariably develop resistance to these drugs. E7820 is an angiogenesis inhibitor that decreases integrin-α2
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2950-25MG | 04065265102186 |
| SML2950-5MG | 04065265102193 |